HER-2低表达患者在乳腺癌中的占比及其临床病理特征

doi:10.3969/j.issn.1004-616x.2024.06.006

摘要/Abstract

摘要： 目的： 研究HER-2低表达患者在乳腺癌中的占比及其临床病理特征。方法： 收集2019年1月—2023年12月间深圳市妇幼保健院收治的982例浸润性乳腺癌患者的癌组织样本，采用免疫组织化学(IHC)法检测癌组织中人类表皮生长因子受体2(HER-2)、雌激素受体(ER)、孕激素受体(PR)以及细胞增殖相关蛋白Ki-67的表达情况，荧光原位杂交(FISH)法检测HER-2基因扩增情况，此外对其他临床病理资料如患者年龄、肿瘤直径、组织学分级、淋巴结转移等进行回顾性研究，分析HER-2低表达患者在乳腺癌中的占比及其与HER-2阴性、HER-2阳性乳腺癌患者间的临床病理特征差异。结果： 982例乳腺癌中HER-2低表达567例(57.74%)，HER-2阴性194例(19.76%)，HER-2阳性221例(22.50%)。HER-2低表达乳腺癌的组织学分级和Ki-67增殖指数均低于HER-2阴性和HER-2阳性乳腺癌(均为P<0.01)；淋巴结转移率高于HER-2阴性乳腺癌，但低于HER-2阳性乳腺癌(均为P<0.01)；激素受体阳性率高于HER-2阳性乳腺癌(P<0.01)，与HER-2阴性乳腺癌的差异无统计学意义(P>0.05)。此外，HER-2低表达乳腺癌患者年龄及肿瘤直径与HER-2阴性和HER-2阳性乳腺癌比较差异均无统计学意义(P>0.05)。结论： HER-2低表达乳腺癌在整体乳腺癌中占比高，且具有组织学分级低、Ki-67增殖指数低、激素受体阳性率高等特点，临床工作中应予以重视。

关键词: 乳腺癌, 人类表皮生长因子受体2, 低表达, 分布

Abstract: OBJECTIVE： To study the proportion of HER-2-low expression in breast cancer and the clinicopathological characteristics of HER-2-low breast cancer. METHODS： From January 2019 to December 2023，982 cases of invasive breast cancer cases that were treated in the Shenzhen Maternal and Child Healthcare Hospital were collected. Immunohistochemistry (IHC) was used to detect the expression of human epidermal growth factor receptor-2 (HER-2)，hormone receptors including estrogen receptor (ER) and progesterone receptor (PR)，and cell proliferation related protein Ki-67. Fluorescence in situ hybridization (FISH) was used to detect HER-2 gene amplification. The clinicopathological data such as the patients-- age，tumor diameter，histological grades of tumor and lymph node metastasis status were retrospectively studied to analyze the proportion of HER-2 low expression in breast cancer cases and the difference in clinicopathological characteristics between HER-2-low breast cancer and HER-2 negative/positive breast cancer. RESULTS： Among the 982 cases，567 (57.74%) were HER-2-low，194 (19.76%) were HER-2 negative，and 221 (22.50%) were HER-2 positive. The histological grade and Ki-67 proliferation index of HER-2-low breast cancer were lower than those of HER-2 negative and HER-2 positive breast cancer (all P<0.01). The lymph node metastasis rate in HER-2-low breast cancer was higher than it in HER-2 negative breast cancer，but lower than it in HER-2 positive breast cancer (all P<0.01). The positive rate of hormone receptors in HER-2-low breast cancer was higher than that in HER-2 positive breast cancer (P<0.01)，but no significant difference with HER-2 negative breast cancer. There was no significant difference between HER-2-low breast cancer and HER-2 negative or HER-2 positive breast cancer in terms of patients-- age and tumor diameter. CONCLUSION： Breast cancer with low HER-2 expression accounted for a high proportion of the overall breast cancer cases，and showed low histological grade，low Ki-67 proliferation index，but high hormone receptor positivity rate. These characteristics may affect therapeutic efficacy.

Key words: breast cancer, HER-2, low expression, distribution

中图分类号:

R737.9

杨怡晖, 张文夏, 龚芷宁, 岑雪雪, 秦琪敏, 汤红平. HER-2低表达患者在乳腺癌中的占比及其临床病理特征[J]. 癌变·畸变·突变, 2024, 36(6): 457-462.

YANG Yihui, ZHANG Wenxia, GONG Zhining, CEN Xuexue, QIN Qimin, TANG Hongping. Clinicopathological characterization of HER-2-low cases among breast cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(6): 457-462.

参考文献

[1] HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[2] MUSOLINO A, NALDI N, BORTESI B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer[J]. J Clin Oncol, 2008, 26(11): 1789-1796.
[3] WOLFF A C, HAMMOND M E H, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122.
[4] MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[5] 中国抗癌协会国际医疗与交流分会, 中国医师协会肿瘤医师分会乳腺癌学组. 人表皮生长因子受体2低表达乳腺癌临床诊疗共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(12): 1288-1295.
[6] TARANTINO P, VIALE G, PRESS M F, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659.
[7] CORTI C, GIUGLIANO F, NICOLÒ E, et al. HER2-low breast cancer: a new subtype?[J]. Curr Treat Options Oncol, 2023, 24(5): 468-478.
[8] HAMMOND M E, HAYES D F, WOLFF A C, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Oncol Pract, 2010, 6(4): 195-197.
[9] 《乳腺癌HER检测指南(版)》编写组. 乳腺癌HER2检测指南(2019版)[J]. 中华病理学杂志, 2019, 48(3): 169-175.
[10] SAREYELDIN R M, GUPTA I, AL-HASHIMI I, et al. Gene expression and miRNAs profiling: function and regulation in human epidermal growth factor receptor 2(HER2)-positive breast cancer[J]. Cancers, 2019, 11(5): 646.
[11] SWAIN S M, KIM S B, CORTÉS J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2013, 14(6): 461-471.
[12] DENKERT C, LEBEAU A, SCHILDHAUS H U, et al. New treatment options for metastatic HER2-low breast cancer: consequences for histopathological diagnosis[J]. Pathologie (Heidelb), 2023, 44(Sup 2): 53-60.
[13] VENETIS K, CRIMINI E, SAJJADI E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer[J]. Front Mol Biosci, 2022, 9: 834651.
[14] SHUI R H, LIANG X Z, LI X M, et al. Hormone receptor and human epidermal growth factor receptor 2 detection in invasive breast carcinoma: a retrospective study of 12, 467 patients from 19 Chinese representative clinical centers[J]. Clin Breast Cancer, 2020, 20(1): e65-e74.
[15] VIALE G, BASIK M, NIIKURA N, et al. Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer[J]. ESMO Open, 2023, 8(4): 101615.
[16] DI COSIMO S, LA ROCCA E, LJEVAR S, et al. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world[J]. Front Mol Biosci, 2022, 9: 996434.
[17] YANG X, LI Y, LU X, et al. Clinicopathological features and prognosis of patients with HER2-low breast cancer[J]. BMC Cancer, 2023, 23(1): 914.
[18] JACOT W, MARAN-GONZALEZ A, MASSOL O, et al. Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers[J]. Cancers, 2021, 13(23): 6059.
[19] CHERIFI F, DA SILVA A, JOHNSON A, et al. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer[J]. BMC Cancer, 2022, 22(1): 1081.
[20] 深圳市统计局. 深圳市第七次全国人口普查主要数据解读[EB/OL].(2021-05-17). http://tjj.sz.gov.cn/ztzl/zt/szsdqcqgrkpc/szrp/content/post_9138049.html.
[21] 汤红平, 黄犁, 张雁瑞, 等. 536例女性乳腺癌患者年龄构成与病理类型分析[J]. 中国妇幼健康研究, 2013, 24(2): 209-210, 218.
[22] YUE M, WU S, LIU C, et al. Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer[J]. Breast Cancer Res Treat, 2024, 203(2): 373-381.
[23] YANG M, SUN J L, LIU L Q, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study[J]. Sci Rep, 2023, 13(1): 12382.
[24] ALMSTEDT K, HEIMES A S, KAPPENBERG F, et al. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer[J]. Eur J Cancer, 2022, 173: 10-19.
[25] ZHANG H N, KATERJI H, TURNER B M, et al. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles[J]. Mod Pathol, 2022, 35(8): 1075-1082.
[26] LI Y J, MAIMAITIAILI A, QU F J, et al. Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study[J]. Am J Cancer Res, 2023, 13(8): 3571-3581.
[27] GUVEN D C, KAYA M B, FEDAI B, et al. HER2-low breast cancer could be associated with an increased risk of brain metastasis[J]. Int J Clin Oncol, 2022, 27(2): 332-339.
[28] SHANG J Y, SUN X M, XU Z H, et al. Evolution and clinical significance of HER2-low status after neoadjuvant therapy for breast cancer[J]. Front Oncol, 2023, 13: 1086480.
[29] 白冰, 张艾佳, 郭新, 等. HER2低表达乳腺癌的临床病理特征和预后因素分析[J]. 中国医科大学学报, 2023, 52(6): 494-498.
[30] ZHANG G C, REN C Y, LI C, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status[J]. BMC Med, 2022, 20(1): 142.
[31] TAN R S Y C, ONG W S, LEE K H, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis[J]. BMC Med, 2022, 20(1): 105.
[32] ZHOU S L, LIU T, KUANG X Y, et al. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer[J]. Breast, 2023, 67: 1-7.
[33] DAI L J, MA D, XU Y Z, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer[J]. Nat Commun, 2023, 14(1): 5112.
[34] LI Y Y, TSANG J Y, TAM F, et al. Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment[J]. EBioMedicine, 2023, 91: 104571.
[35] 国家卫生健康委员会医政医管局. 乳腺癌诊疗指南(2022年版) [EB/OL]. (2022-04-03). http://www.nhc.gov.cn/yzygj/s7659/ 202204/a0e67177df1f439898683e1333957c74/files/c001a73dfefc 4ace889a1ea6e0230865.pdf.